Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.

Nelson MR, Bacanu SA, Mosteller M, Li L, Bowman CE, Roses AD, Lai EH, Ehm MG.

Pharmacogenomics J. 2009 Feb;9(1):23-33. doi: 10.1038/tpj.2008.4. Epub 2008 Feb 26.

PMID:
18301416
2.

Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions.

Thygesen H, Su TL, Whitehead J, Bowman C.

J Biopharm Stat. 2011 Jan;21(1):111-24. doi: 10.1080/10543401003602615.

PMID:
21191858
3.

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.

Roses AD.

Neuropsychopharmacology. 2009 Jan;34(1):6-17. doi: 10.1038/npp.2008.153. Epub 2008 Oct 15. Review.

4.

[Prospective validation of a pharmacogenetic test: the PREDICT-1 study].

Muñoz de Benito RM, Arribas López JR.

Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 6:40-4. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2008 Oct;26(8):536.

PMID:
18680695
5.

Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.

Berka N, Gill JM, Liacini A, O'Bryan T, Khan FM.

Hum Immunol. 2012 Feb;73(2):164-7. doi: 10.1016/j.humimm.2011.12.002. Epub 2011 Dec 8.

PMID:
22197535
6.

PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.

Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D; CNA106030 Study Team.

Pharm Stat. 2008 Apr-Jun;7(2):121-9.

PMID:
17534855
7.

Pharmacogenetics of drug hypersensitivity.

Phillips EJ, Mallal SA.

Pharmacogenomics. 2010 Jul;11(7):973-87. doi: 10.2217/pgs.10.77. Review.

8.

HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.

Lucas A, Nolan D, Mallal S.

J Antimicrob Chemother. 2007 Apr;59(4):591-3. Epub 2007 Feb 22.

PMID:
17317695
9.

Abacavir hypersensitivity: a model system for pharmacogenetic test adoption.

Lai-Goldman M, Faruki H.

Genet Med. 2008 Dec;10(12):874-8. doi: 10.1097/GIM.0b013e31818de71c. Review.

PMID:
19092439
10.

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.

Hughes AR, Spreen WR, Mosteller M, Warren LL, Lai EH, Brothers CH, Cox C, Nelsen AJ, Hughes S, Thorborn DE, Stancil B, Hetherington SV, Burns DK, Roses AD.

Pharmacogenomics J. 2008 Dec;8(6):365-74. doi: 10.1038/tpj.2008.3. Epub 2008 Mar 11. Review.

PMID:
18332899
11.

Pharmacogenetic markers of severe cutaneous adverse drug reactions.

Borroni RG.

G Ital Dermatol Venereol. 2014 Apr;149(2):219-26. Review.

PMID:
24819643
12.

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.

Hughes AR, Brothers CH, Mosteller M, Spreen WR, Burns DK.

Pharmacogenomics. 2009 Feb;10(2):225-33. doi: 10.2217/14622416.10.2.225. Review.

PMID:
19207023
13.

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M.

Pharmacogenetics. 2004 Jun;14(6):335-42.

PMID:
15247625
14.

Human leukocyte antigens and drug hypersensitivity.

Chung WH, Hung SI, Chen YT.

Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):317-23. Review.

PMID:
17620823
15.

HLA-B*5701 screening for hypersensitivity to abacavir.

Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team.

N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.

16.

Abacavir hypersensitivity reaction: an update.

Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE.

Ann Pharmacother. 2008 Mar;42(3):387-96. doi: 10.1345/aph.1K522. Epub 2008 Feb 26. Review.

PMID:
18303141
17.

Pharmacogenomics of adverse drug reactions: implementing personalized medicine.

Wei CY, Lee MT, Chen YT.

Hum Mol Genet. 2012 Oct 15;21(R1):R58-65. Epub 2012 Aug 19. Review.

PMID:
22907657
18.

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.

Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD; CNA30027 Study Team; CNA30032 Study Team.

Pharmacogenomics. 2004 Mar;5(2):203-11.

PMID:
15016610
19.

Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity.

Guéant JL, Guéant-Rodriguez RM, Gastin IA, Cornejo-García JA, Viola M, Barbaud A, Mertes PM, Blanca M, Romano A.

Curr Pharm Des. 2008;14(27):2770-7. Review.

PMID:
18991696
20.

Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.

Alfirevic A, Pirmohamed M.

Pharmacogenomics. 2010 Apr;11(4):497-9. doi: 10.2217/pgs.10.12.

Supplemental Content

Support Center